Research programme: next-generation virulizin compounds - Lorus Therapeutics
Alternative Names: Neo-virulizin; Next-generation virulizin compounds research programme - LorusLatest Information Update: 29 Feb 2008
At a glance
- Originator Lorus Therapeutics
- Class Bile acids and salts
- Mechanism of Action Macrophage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Feb 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 02 Nov 2005 This programme is still in active development
- 05 Nov 2004 Preclinical trials in Cancer in USA (unspecified route)